Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-infer... by Jørgensen, Kristin K, PhD, Olsen, Inge C, PhD, Goll, Guro L, PhD, Lorentzen, Merete, MD, Bolstad, Nils, MD, Haavardsholm, Espen A, Prof, Lundin, Knut E A, Prof, Mørk, Cato, Prof, Jahnsen, Jørgen, Prof, Kvien, Tore K, Prof

Get full text

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial by Goll, G. L., Jørgensen, K. K., Sexton, J., Olsen, I. C., Bolstad, N., Haavardsholm, E. A., Lundin, K. E. A., Tveit, K. S., Lorentzen, M., Berset, I. P., Fevang, B. T. S., Kalstad, S., Ryggen, K., Warren, D. J., Klaasen, R. A., Asak, Ø., Baigh, S., Blomgren, I. M., Brenna, Ø., Bruun, T. J., Dvergsnes, K., Frigstad, S. O., Hansen, I. M., Hatten, I. S. H., Huppertz‐Hauss, G., Henriksen, M., Hoie, S. S., Krogh, J., Midtgard, I. P., Mielnik, P., Moum, B., Noraberg, G., Poyan, A., Prestegård, U., Rashid, H. U., Strand, E. K., Skjetne, K., Seeberg, K. A., Torp, R., Ystrøm, C. M., Vold, C., Zettel, C. C., Waksvik, K., Gulbrandsen, B., Hagfors, J., Mørk, C., Jahnsen, J., Kvien, T. K.

Get full text

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial by Goll, Guro Løvik, Jørgensen, Kristin Kaasen, Sexton, Joseph, Olsen, Inge Christoffer, Bolstad, Nils, Haavardsholm, Espen A, Lundin, Knut Erik Aslaksen, Tveit, Kåre Steinar, Lorentzen, Merete, Berset, Ingrid Prytz, Fevang, Bjørg-Tilde Svanes, Kalstad, Synnøve, Ryggen, Kristin, Warren, David, Klaasen, Rolf, Asak, Øivind Wessel, Baigh, Somyeh, Blomgren, Ingrid, Brenna, Øystein, Bruun, Trude J, Dvergsnes, Katrine, Frigstad, Svein Oskar, Myrnes, Inger, Hatten, Ingvild Helgheim, Huppertz-Hauss, Gert, Henriksen, Magne, Hoie, Sunniva S, Krogh, Jan Reidar, Midtgard, Irina P, Mielnik, Pawel, Moum, Bjørn, Noraberg, Geir, Poyan, Armin, Prestegård, Ulf, Rashid, Haroon Ur, Strand, Eldri Kveine, Skjetne, Kristine, Seeberg, Kathrine, Torp, Roald, Ystrøm, Carl Magnus, Vold, Cecilia, Zettel, Camilla C, Waksvik, Kenneth, Gulbrandsen, Bjørn, Hagfors, Jon, Mørk, Cato, Jahnsen, Jørgen, Kvien, Tore Kristian

Request full text

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial by Goll, Guro Løvik, Jørgensen, Kristin Kaasen, Sexton, Joseph, Olsen, Inge Christoffer, Bolstad, Nils, Haavardsholm, Espen A, Lundin, Knut Erik Aslaksen, Tveit, Kåre Steinar, Lorentzen, Merete, Berset, Ingrid Prytz, Fevang, Bjørg-Tilde Svanes, Kalstad, Synnøve, Ryggen, Kristin, Warren, David, Klaasen, Rolf, Asak, Øivind Wessel, Baigh, Somyeh, Blomgren, Ingrid, Brenna, Øystein, Bruun, Trude J, Dvergsnes, Katrine, Frigstad, Svein Oskar, Myrnes, Inger, Hatten, Ingvild Helgheim, Huppertz-Hauss, Gert, Henriksen, Magne, Hoie, Sunniva S, Krogh, Jan Reidar, Midtgard, Irina P, Mielnik, Pawel, Moum, Bjørn, Noraberg, Geir, Poyan, Armin, Prestegård, Ulf, Rashid, Haroon Ur, Strand, Eldri Kveine, Skjetne, Kristine, Seeberg, Kathrine, Torp, Roald, Ystrøm, Carl Magnus, Vold, Cecilia, Zettel, Camilla C, Waksvik, Kenneth, Gulbrandsen, Bjørn, Hagfors, Jon, Mørk, Cato, Jahnsen, Jørgen, Kvien, Tore Kristian

Request full text